This inventor holds 24 USPTO granted patents and 4 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bayer Aktiengesellschaft, Xention Limited, Axikin Pharmaceuticals, Inc.. Active years: 2002-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Kobe, JP (2003)
- Wuppertal, DE (2002 - 2006)
- Hyogo, JP (2009 - 2012)
- Hyogo-ken, JP (2010 - 2012)
- Lund, SE (2008 - 2015)
Company Filing History:
6 out of 12,266 
6 out of 22 
4 out of 23 
Years Active: 2002-2015
Areas of Expertise:
Title: Innovations of Klaus Urbahns in Pharmaceutical Chemistry
Introduction
Klaus Urbahns is a prominent inventor based in Lund, Sweden, with a remarkable portfolio of 24 patents. His innovative contributions primarily focus on developing compounds with potential applications in treating various inflammatory and immunological disorders.
Latest Patents
Among Klaus Urbahns' latest patents are significant advancements in the field of pharmaceutical chemistry. One of his notable inventions includes “2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders.” This invention provides compounds that target CCR3 activity and are designed to treat diseases such as atopic dermatitis, allergic rhinitis, rheumatoid arthritis, Grave's disease, HIV infection, Alzheimer's disease, and atherosclerosis.
Another important patent is the development of “arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders.” This invention introduces a sulfonamide derivative that serves as an active ingredient in pharmaceutical preparations, particularly targeting conditions associated with CCR3 activity, including asthma and other related disorders.
Career Highlights
Klaus Urbahns has made significant contributions to the pharmaceutical industry through his roles at reputable companies such as Bayer Aktiengesellschaft and Xention Limited. His innovative work has been instrumental in developing therapies that address critical health issues.
Collaborations
Throughout his career, Klaus has collaborated with notable scientists, including Toshiya Moriwaki and Kevin Bacon. These collaborations have further enhanced his research and development efforts, leading to groundbreaking inventions that serve the medical community.
Conclusion
Klaus Urbahns continues to impact the field of pharmaceutical chemistry with his innovative approaches to treating complex diseases. His extensive patent portfolio reflects his commitment to advancing medical science and improving patient outcomes through novel therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile